Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug AIR-001 enters first human tests for rare lung condition

NCT ID NCT07431112

Recruiting now Disease control Sponsor: AIRNA Corporation Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial tests a new drug called AIR-001 in 54 adults with alpha-1 antitrypsin deficiency (AATD) who have a specific genetic type (PiZZ). The study aims to check safety and how the body processes the drug. Participants receive increasing doses of AIR-001 under the skin to find the best and safest levels.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

AIR-001

What this could lead to

If successful, this could lead to a new treatment that helps control lung damage in people with alpha-1 antitrypsin deficiency.

What could go wrong

This is a very early Phase 1 trial with only 54 people, focused on safety. It is too soon to know if AIR-001 will work or be safe long-term.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALPHA 1-ANTITRYPSIN DEFICIENCY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

alpha 1-antitrypsin deficiency Congenital Abnormalities hereditary disease Infant, Newborn, Diseases liver disorder lung disorder Pathologic Processes Pathological Conditions, Signs and Symptoms pulmonary emphysema respiratory system disorder Subcutaneous Emphysema

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ALPHA 1-ANTITRYPSIN DEFICIENCY

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Clinical Study Center

    RECRUITING

    Melbourne, Australia

  • Clinical Study Center

    RECRUITING

    London, United Kingdom

  • Clinical Study Center 1

    RECRUITING

    Tbilisi, Georgia

  • Clinical Study Center 2

    RECRUITING

    Tbilisi, Georgia